Press release from PR Newswire
Questcor Announces Second Quarter 2010 Earnings Release Date and Conference Call
Thursday, July 15, 2010
Questcor Announces Second Quarter 2010 Earnings Release Date and Conference Call06:30 EDT Thursday, July 15, 2010UNION CITY, Calif., July 15 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release financial results for the second quarter ended June 30, 2010 on Wednesday, July 28, 2010 after the market close. �The Company will host a conference call and webcast on Wednesday, July 28, 2010 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the Company's second quarter results and current corporate developments. �The dial-in number for the conference call is 866-225-8754 for domestic participants and 480-629-9692 for international participants.A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. �This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4330467#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at www.questcor.com. An archived webcast will also be available at www.questcor.com.About QuestcorQuestcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar� Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral� (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com. SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey of Questcor Pharmaceuticals, Inc., +1-510-400-0776, dbailey@Questcor.com; or Investors, Barbara Domingo or Doug Sherk, +1-415-896-6820, or Media, Janine McCargo, +1-646-201-5431, all of EVC Group, for Questcor Pharmaceuticals, Inc.